Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Phase 2 Withdrawn
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Phase 1 Withdrawn
CheckCell-2
Phase 1/2 Withdrawn
MK-5890-003
Phase 2 Withdrawn
PULSAR
Phase 2 Withdrawn
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Phase 1/2 Withdrawn
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 1/2 Withdrawn
NeoSarc
Phase 2 Withdrawn
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Phase 2 Withdrawn
PSMA Therapy and Immunotherapy in Kidney Cancer
Phase 1/2 Withdrawn
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Phase 2 Withdrawn
Abemaciclib + Pembrolizumab In Glioblastoma
Phase 2 Withdrawn
PRIMUS006
Phase 2 Withdrawn
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Phase 1/2 Withdrawn
TALON
Phase 2 Withdrawn
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Phase 2/3 Withdrawn
LN-144
Phase 1 Withdrawn
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Phase 1/2 Withdrawn
MK-9999-01B
Phase 1/2 Withdrawn
SOC-2320
Phase 2 Withdrawn
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
Phase 2 Withdrawn
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Phase 1/2 Withdrawn
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Phase 2 Withdrawn
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
Phase 2 Withdrawn
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Phase 2 Withdrawn
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
Phase 2 Withdrawn
Pembrolizumab in Early Stage Colon Cancer
Phase 2 Withdrawn
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Phase 2 Withdrawn
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Phase 2 Withdrawn
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
Phase 2 Withdrawn
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Phase 1 Withdrawn
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
Phase 2 Withdrawn
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Phase 1/2 Withdrawn
PELICAN
Phase 2 Withdrawn
Axitinib Therapy Management Study
Withdrawn
CARMA
Phase 2 Withdrawn
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Phase 2 Withdrawn
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
Phase 2 Withdrawn
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Phase 2 Withdrawn
AdvanTIG-306
Phase 3 Withdrawn
AdvanTIG-211
Phase 2 Withdrawn
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
Phase 1 Withdrawn
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Phase 2 Withdrawn
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase 1 Withdrawn
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Phase 2 Withdrawn
Sargramostim (GM-CSF) + PD-1
Phase 2 Withdrawn
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Phase 1 Withdrawn
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
Phase 2 Withdrawn
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Phase 1/2 Withdrawn
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
Phase 2 Withdrawn